Literature DB >> 8827400

Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems.

N G Schneider1, E Lunell, R E Olmstead, K O Fagerström.   

Abstract

Rapid drug delivery (arterial "boli') and high drug concentrations occur with nicotine inhaled in smoke. These are believed to be key elements in producing addiction to cigarettes. Preparations which reduce the rate of delivery and/or concentration of nicotine have been introduced as treatments for smoking cessation. These nicotine medications work by relieving withdrawal and preventing relapse associated with abrupt cessation of smoking. The pharmacokinetics of each system are expected to affect efficacy and treatment dependence. Nasal administration systems have been developed to more closely approximate cigarette delivery for improved efficacy in clinical application and for more control in systematic testing of nicotine. With laboratory tested nasal application systems (clinical drug and experimental devices), venous plasma concentrations after a single dose range between 5 and 12 micrograms/L. Higher steady-state blood nicotine concentrations (16 to 29 micrograms/L) have been reported for ad libitum clinical self-administration with a nicotine nasal spray. Time to peak plasma concentration (tmax) with nasal administration is around 11 to 13 minutes for 1 mg doses. This rise time is slower than for cigarette delivery but faster than the other nicotine treatments. Venous plasma concentrations are considerably lower than tobacco product concentrations and fall within the range of the lower dose nicotine treatments (e.g. 2 mg gum vs 4 mg gum). The profile of nasal nicotine administration was designed for certain subsets of smokers. Efficacy trials show consistent superiority of nasal administration over placebo although the comparative efficacy among nicotine treatments remains to be determined. The more rapid onset and user control of nasal nicotine may impose a higher risk for treatment dependence compared with a slower, passive system such as the patch. It may not produce more dependence than other faster-acting treatment systems (e.g. nicotine gum).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827400     DOI: 10.2165/00003088-199631010-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  41 in total

Review 1.  Nicotine therapy in smoking cessation. Pharmacokinetic considerations.

Authors:  N G Schneider
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 2.  Pharmacokinetic considerations in abuse liability evaluation.

Authors:  M Farré; J Camí
Journal:  Br J Addict       Date:  1991-12

3.  Nasal nicotine solution as an aid to cigarette withdrawal: a pilot clinical trial.

Authors:  M J Jarvis; P Hajek; M A Russell; R J West; C Feyerabend
Journal:  Br J Addict       Date:  1987-09

4.  Plasma nicotine concentrations from repeated doses of nasal nicotine solution.

Authors:  R J West; M J Jarvis; M A Russell; C Feyerabend
Journal:  Br J Addict       Date:  1984-12

5.  Relative bioavailability of nicotine from a nasal spray in infectious rhinitis and after use of a topical decongestant.

Authors:  E Lunell; L Molander; M Andersson
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 6.  Cigarette smoking and nicotine addiction.

Authors:  N L Benowitz
Journal:  Med Clin North Am       Date:  1992-03       Impact factor: 5.456

7.  Comparison of nicotine chewing-gum and psychological treatments for dependent smokers.

Authors:  M Raw; M J Jarvis; C Feyerabend; M A Russell
Journal:  Br Med J       Date:  1980-08-16

8.  Determinants of nicotine intake while chewing nicotine polacrilex gum.

Authors:  N L Benowitz; P Jacob; C Savanapridi
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

9.  Controlled dosing of nicotine via an Intranasal Nicotine Aerosol Delivery Device (INADD).

Authors:  O F Pomerleau; K A Flessland; C S Pomerleau; M Hariharan
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 10.  Nicotine delivery kinetics and abuse liability.

Authors:  J E Henningfield; R M Keenan
Journal:  J Consult Clin Psychol       Date:  1993-10
View more
  24 in total

Review 1.  Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability.

Authors:  C T Sweeney; R V Fant; K O Fagerstrom; J F McGovern; J E Henningfield
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Smoking produces rapid rise of [11C]nicotine in human brain.

Authors:  Marc S Berridge; Scott M Apana; Kenichi K Nagano; Catherine E Berridge; Gregory P Leisure; Mark V Boswell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

Review 3.  Tobacco Use Cessation and Prevention - A Review.

Authors:  Sabiha Shaheen Shaik; Dolar Doshi; Srikanth Reddy Bandari; Padma Reddy Madupu; Suhas Kulkarni
Journal:  J Clin Diagn Res       Date:  2016-05-01

4.  Comparison of three nicotine treatments: initial reactions and preferences with guided use.

Authors:  Nina G Schneider; Scott Terrace; Margaret A Koury; Shilpan Patel; Behram Vaghaiwalla; Regina Pendergrass; Richard E Olmstead; Chris Cortner
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 5.  A review of smoking cessation interventions.

Authors:  Ashish Maseeh; Gagandeep Kwatra
Journal:  MedGenMed       Date:  2005-06-07

6.  Positive effects of nicotine on cognition: the deployment of attention for prospective memory.

Authors:  J M Rusted; R Sawyer; C Jones; S L Trawley; N L Marchant
Journal:  Psychopharmacology (Berl)       Date:  2008-09-25       Impact factor: 4.530

Review 7.  Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.

Authors:  Edwin J Wagena; Maurice P A Zeegers; Constant P van Schayck; Emiel F M Wouters
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 8.  The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments.

Authors:  N G Schneider; R E Olmstead; M A Franzon; E Lunell
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers.

Authors:  Natalie L Marchant; Sarah L King; Naji Tabet; Jennifer M Rusted
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

10.  Treating tobacco dependence in a medical setting.

Authors:  Richard D Hurt; Jon O Ebbert; J Taylor Hays; David D McFadden
Journal:  CA Cancer J Clin       Date:  2009-08-25       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.